Update on spring 2025 vaccination programs: Respiratory Syncytial Virus (RSV) and COVID-19 To: Local Health System Partners

Cette information est seulement disponible en anglais.

Advisory Alert

To: Local Health System Partners

April 14, 2025

The 2024-2025 adult RSV program will continue into spring. Refer to the Ministry of Health website for high-risk older adult eligibility criteria.
The 2024-2025 infant and high-risk children RSV prevention program has ended.
- Doses of Beyfortus and Abrysvo should no longer be ordered or administered to infants, children, or pregnant individuals.
If you have non-expired inventory, please keep and store it under appropriate cold chain conditions for use next season.

In spring 2025, high-risk individuals who have completed a primary series are recommended to receive an additional dose of the COVID-19 vaccine.
Vaccination for high-risk individuals is recommended between April and June, but doses can be administered until August 31, 2025.
Spring doses are recommended to be administered 6 months or more after the previous dose of COVID-19 vaccine; however, the dose may be administered as early as 3 months after the previous dose.
For eligibility criteria, refer to the Health Care Provider Fact Sheet: 2024/2025 COVID-19 Vaccine Program – Update (Ministry of Health, PDF).
Individuals who are not high-risk are not recommended to receive dose(s) in the spring, regardless of if dose(s) were received in the fall. It is recommended those individuals be vaccinated during the next annual COVID-19 vaccine program to ensure optimal protection against circulating strains.

To order a vaccine, please complete the Respiratory Vaccine Order Form (PDF) and email it to vaccineorder@phsd.caor fax it to 705.677.9616.
To report an adverse event following immunization, complete the AEFI reporting form (PDF) and fax it to 705.677.9616.
To reactivate your COVax account or for those creating a new account, please email COVaxAccounts@phsd.ca.
For immunization inquiries, call the Vaccine Preventable Diseases program at 705.522.9200, ext. 458 (toll-free 1.866.522.9200).

Sincerely,

Original Signed By

Mustafa Hirji, MD, MPH, FRCPC
Acting Medical Officer of Health and Chief Executive Officer

Note: All Advisory Alerts are found on our website

This item was last modified on April 14, 2025